prezista (darunavir) availability of 800 mg tablet strength

FDA News Prezista (darunavir) availability of 800 mg tablet strength Richard Klein and Kimberly Struble FDA News
November 14, 2012

FDA recently approved availability of an 800 mg tablet strength for Prezista (darunavir), an HIV-1 protease inhibitor (PI) indicated for the treatment of HIV-1 infection. The Dosage and Administration section has been changed, in part, to read: Treatment-naïve adult patients and treatment-experienced adult patients with no darunavir resistance associated substitutions: 800 mg (one 800 mg tablet or two 400 mg tablets) taken with ritonavir 100 mg once daily and with food. Prezista is a product of Janssen Pharmaceuticals, Inc. Richard Klein Office of Special Health Issues Food and Drug Administration Kimberly Struble Division of Antiviral Products Food and Drug Administration

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Photographs from A Day with HIV Now Online Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 Positive living Lawyer: NY man at center of HIV scare not positive Zimbabwe activist: Prisoners denied AIDS drugs Youth organizations form a pact for social transformation in the AIDS response CountyCare Offers Historic Opportunity to Improve Care for People with HIV International AIDS Advocates Demand China Give $1 Billion to Global Fund Kingdom of Bahrain and UNAIDS commit to intensify cooperation CANADA: Celibate Homosexual Men Now Allowed to Donate Blood in Canada AFRICA: UN: AIDS Deaths Down, Treatment Up in Africa MICHIGAN: STD Fee for Jackson County Walk-In Clinic Takes Effect June 3 Tentative approval of lamivudine and tenofovir disoproxil fumarate Tablets, 300 mg/300 mg Prezista (darunavir) labeling changes Changes to label for Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) tablets South Africa: Simple ARV Tablet Rolled Out Tentative approval: efavirenz, emtricitabine and tenofovir Disoproxil fumarate tablets, 600 mg/200 mg/300 mg New Superiority Trial Showed LIVALO® pitavastatin 4 mg Provided Significantly Greater LDL-C Reduction in HIV-Infected Adults with Dyslipidemia versus Pravastatin 40 mg New Superiority Trial Showed LIVALO(R) (pitavastatin) 4 mg Provided Significantly Greater LDL-C Reduction in HIV-Infected Adults with Dyslipidemia versus Pravastatin 40 mg: Study results presented as late-breaker at CROI 2013 this week Prezista (darunavir) label change - drug interaction information TEXAS: Food Availability Linked with Poor Outcomes for HIV-Positive Children Video Now Available: U.S. FDA Approves Bayer's Skyla(TM) (Levonorgestrel-Releasing Intrauterine System) 13.5 mg For Prevention Of Pregnancy For Up To Three Years
Copyright © 2012 -FDA News, Publisher. All rights reserved to Food and Drug (FDA) Administration FDA. Information in this article was accurate in November 14, 2012. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.